Aller au contenu principal
Profil bibliographique

Xiaozhuo Liu

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

43Publications signalées
898Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Prostate Cancer Treatment and ResearchRNA Research and SplicingMicroRNA in disease regulationRNA modifications and cancerCancer-related gene regulation

Les publications récentes

Accès ouvert 2026 article OpenAlex

Protein Arginine Methylation of the Translation Initiation Factor eIF1A Increases Usage of a Near-cognate Start Codon

Rebecca Wegman, Michael Langberg, Haiteng Deng, Yuling Chen et autres

Protein arginine methylation has emerged as a key post-translational modification responsible for many facets of eukaryotic gene expression. To better understand the extent of this modification in cellular pathways, we carried out bioorthogonal methylation profiling in Saccharomyces cerevisiae to comprehensively identify the …

us, cn (code pays fourni par la source)

0 citations Molecular & Cellular Proteomics
Accès ouvert 2026 preprint OpenAlex

STAG2 Maintains Chromatin Compartmentalization and Represses Regulatory Element Contact to Promote Oncogenic Signaling in Muscle Invasive Bladder Cancer

Sarah R. Athans, Jiaojiao Zhou, Xiaozhuo Liu, Eduardo Cortes Gomez et autres

ABSTRACT Contrary to other cancer types, stromal antigen 2 (STAG2) expression is associated with shorter survival and an invasive phenotype in muscle invasive bladder cancer (MIBC). As a cohesin complex component, STAG2 regulates genome organization and cell type-specific transcription, yet its mechanistic …

us, ar (code pays fourni par la source)

0 citations bioRxiv (Cold Spring Harbor Laboratory)
Accès ouvert 2026 preprint OpenAlex

A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer

Kathryn E. Maraszek, Arwen A. Tisdale, Hunter D. Reavis, Xiaozhuo Liu et autres

Pancreatic ductal adenocarcinoma (PDAC) is an intractable disease with few effective treatment options. PDAC is characterized by a dense, fibro-inflammatory tumor microenvironment (TME) consisting mainly of cancer-associated fibroblasts (CAFs) and a CAF-generated collagen-rich extracellular matrix (ECM). As the ECM has profound impacts …

us, au (code pays fourni par la source)

0 citations bioRxiv (Cold Spring Harbor Laboratory)
Accès ouvert 2025 article OpenAlex

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer

Stuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain et autres

PURPOSE: Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be effectively targeted by combining enzalutamide with the BCL-2 inhibitor venetoclax. EXPERIMENTAL DESIGN: This …

us, ae (code pays fourni par la source)

4 citations Cancer Chemotherapy and Pharmacology
2025 conference-abstract OpenAlex

Abstract A042: Opioids drive extracellular matrix remodeling in the pancreatic tumor microenvironment

Kathryn E. Maraszek, Hunter D. Reavis, Arwen A. Tisdale, Xiaozhuo Liu et autres

Abstract Pancreatic cancer is a highly lethal malignancy with a 5-year survival rate of 13.3%. The disease is characterized by a dense, desmoplastic stroma comprised of extracellular matrix (ECM) proteins produced by cancer-associated fibroblasts (CAFs). This dense ECM has profound impacts on …

us (code pays fourni par la source)

0 citations Cancer Research
Accès ouvert 2025 preprint OpenAlex

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes

Anmbreen Jamroze, Xiaozhuo Liu, Wen Li, Han Yu et autres

ABSTRACT BCL-2 has been implicated in prostate cancer (PCa) progression and development of castration-resistant disease (CRPC). However, it remains unclear how the BCL-2- and AR-expressing PCa cell populations evolve across the PCa continuum, how AR molecularly regulates BCL-2 and whether BCL-2 represents …

us (code pays fourni par la source)

2 citations bioRxiv (Cold Spring Harbor Laboratory)
Accès ouvert 2025 preprint OpenAlex

Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62

Daric J. Wible, Wen Li, Xiaozhuo Liu, Manu Sebastian et autres

ABSTRACT Loss-of-function mutations in autophagy-related (ATG) genes are rare in cancer. However, we report herein that ATG5 is fully deleted in ∼14% of prostate cancers (PCa), rivaling that of well-established tumor suppressor genes. ATG5 expression was downregulated at both mRNA and protein …

us (code pays fourni par la source)

0 citations bioRxiv (Cold Spring Harbor Laboratory)
Accès ouvert 2025 preprint OpenAlex

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival

Xiaozhuo Liu, Anmbreen Jamroze, Eduardo Cortes, Yibing Ji et autres

Abstract Background Cancer progression is often accompanied by dedifferentiation and acquisition of stem cell-like properties (stemness). In prostate cancer (PCa), lineage plasticity and therapy resistance remain major clinical challenges, yet a unified quantitative transcriptomic framework connecting stemness, androgen receptor (AR) signaling, castration …

us, au, cn (code pays fourni par la source)

1 citation bioRxiv (Cold Spring Harbor Laboratory)
Accès ouvert 2025 preprint OpenAlex

Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer

Stuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain et autres

ABSTRACT Purpose Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be effectively targeted by combining enzalutamide with the BCL-2 inhibitor venetoclax. Experimental Design …

us (code pays fourni par la source)

1 citation medRxiv
Accès ouvert 2025 article OpenAlex

The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis

Xu Zhao, Xianhao Huo, Ran Zhao, Xiaozhuo Liu et autres

Objective: Our group aimed to explore the effect of different dosages of citicoline on ischemic stroke (IS) patients and determine the most appropriate dosage for these patients. Methods: The databases of PubMed, Cochrane Library, Medline, Web of Science, and Embase were searched …

cn (code pays fourni par la source)

6 citations Frontiers in Pharmacology
Accès ouvert 2024 article OpenAlex

Treatment options for unilateral vestibular schwannoma: a network meta-analysis

Xianhao Huo, Xu Zhao, Xiaozhuo Liu, Yifan Zhang et autres

This study aimed to explore the effect of observation, microsurgery, and radiotherapy for patients with vestibular schwannoma (VS). We searched PubMed, Medline, Embase, Web of Science, and Cochrane library from their establishment to July 31, 2024. 34 non-RCTs and 1 RCT that …

cn (code pays fourni par la source)

8 citations BMC Cancer
Accès ouvert 2024 article OpenAlex

Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis

Mei Li, Xianhao Huo, Qing Chang, Xiaozhuo Liu et autres

Objective: This network meta-analysis aims to explore the efficacy and safety of neuroprotective agents in patients with ischemic stroke and attempts to identify which drug is the most effective in improving outcomes for patients with acute ischemic stroke (AIS) through a ranking …

cn (code pays fourni par la source)

6 citations Frontiers in Pharmacology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.